Abingworth taps biopharma’s appetite for risk-sharing
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
Esker joins the Tyk2 race
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
C4X shows being early to the party can bring success
Very early stage deals could be the way for C4X to avoid the funding desert that has scuppered so many other UK biotechs.
Prilenia hopes to buck the Huntington’s trend
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
Cognito’s Alzheimer’s brainwave
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
Point’s path leads to a Spac
The radiopharmaceutical researcher was negotiating a series B funding round when it got an offer from a Spac that it could not refuse.
A Spac makes it happen for 4D Pharma
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
Onduo takes its time
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
